Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 18

Results For "Inc."

424 News Found

Lupin receives approval from USFDA for Pirfenidone Tablets
Drug Approval | August 28, 2023

Lupin receives approval from USFDA for Pirfenidone Tablets

This product will be manufactured at Lupin's Pithampur facility in India


Glenmark Pharmaceuticals USA reaches antitrust settlement with DOJ
News | August 24, 2023

Glenmark Pharmaceuticals USA reaches antitrust settlement with DOJ

The company has entered into a three-year Deferred Prosecution Agreement


LEO Pharma to acquire Timber Pharmaceuticals
News | August 22, 2023

LEO Pharma to acquire Timber Pharmaceuticals

The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million


Former Bayer Pharma CEO Dieter Weinand joins Coya’s Board of Directors
People | August 22, 2023

Former Bayer Pharma CEO Dieter Weinand joins Coya’s Board of Directors

Weinand is the former CEO and Chairman of the Board at Bayer Pharma AG, leading Bayer’s fully integrated $20 billion healthcare business


Lupin receives approval from USFDA for Bromfenac Ophthalmic
News | August 20, 2023

Lupin receives approval from USFDA for Bromfenac Ophthalmic

Bromfenac Ophthalmic Solution 0.09% (RLD Bromday) had estimated annual sales of USD 11 million in the U.S. (IQVIA MAT June 2023).


Eugia Pharma receives USFDA Approval for Icatibant Injection
Drug Approval | August 16, 2023

Eugia Pharma receives USFDA Approval for Icatibant Injection

This is the 166th ANDA out of Eugia Pharma Speciality Group facilities


Lupin receives USFDA approval for fluocinolone acetonide body oil
Drug Approval | August 09, 2023

Lupin receives USFDA approval for fluocinolone acetonide body oil

Fluocinolone Acetonide Oil (RLD Derma-Smoothe/FS®) had estimated annual sales of USD 10 million in the U.S. (IQVIA MAT June 2023)


Granules Pharmaceuticals successfully completes USFDA post marketing adverse drug experience inspection with zero observations
Drug Approval | August 05, 2023

Granules Pharmaceuticals successfully completes USFDA post marketing adverse drug experience inspection with zero observations

The inspection was conducted at Granules Pharmaceuticals Inc. (GPI) from July 31, 2023 to August 03, 2023


Supriya Lifescience collaborates with Plasma Nutrition for protein technology
News | August 03, 2023

Supriya Lifescience collaborates with Plasma Nutrition for protein technology

The primary purpose of this collaboration is to bring the optimized protein into the Indian market


TransCure bioServices partners with Preclina to expands reach into APAC
Biotech | July 26, 2023

TransCure bioServices partners with Preclina to expands reach into APAC

Preclina is renowned for its highly specialized services in autoimmune and inflammatory disorders